MX2018001903A - Inhibidores de mdm2 para el tratamiento de melanoma uveal. - Google Patents
Inhibidores de mdm2 para el tratamiento de melanoma uveal.Info
- Publication number
- MX2018001903A MX2018001903A MX2018001903A MX2018001903A MX2018001903A MX 2018001903 A MX2018001903 A MX 2018001903A MX 2018001903 A MX2018001903 A MX 2018001903A MX 2018001903 A MX2018001903 A MX 2018001903A MX 2018001903 A MX2018001903 A MX 2018001903A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- uveal melanoma
- disclosure
- Prior art date
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title abstract 3
- 201000005969 Uveal melanoma Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940083338 MDM2 inhibitor Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación se refiere a una combinación farmacéutica, por ejemplo, un producto, que comprende una combinación de (a) un inhibidor de MDM2 de fórmula I o fórmula II, o una de sus sales farmacéuticamente aceptables, y un inhibidor de la vía de PKC de fórmula III, fórmula IV, fórmula V o fórmula VI, o una de sus sales farmacéuticamente aceptables, particularmente, para el uso en el tratamiento o la prevención de enfermedades proliferativas. La divulgación además se refiere a correspondientes formulaciones farmacéuticas, usos, métodos, combinaciones, soportes de datos y formas de realización de la divulgación relacionadas. La divulgación se refiere adicionalmente al uso de un inhibidor de MDM2 de fórmula I o fórmula II, o una de sus sales farmacéuticamente aceptables, solo en el tratamiento de una enfermedad proliferativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205033P | 2015-08-14 | 2015-08-14 | |
| PCT/IB2016/054841 WO2017029588A2 (en) | 2015-08-14 | 2016-08-11 | Pharmaceutical combinations and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001903A true MX2018001903A (es) | 2018-06-20 |
Family
ID=56851653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001903A MX2018001903A (es) | 2015-08-14 | 2016-08-11 | Inhibidores de mdm2 para el tratamiento de melanoma uveal. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180243293A1 (es) |
| EP (1) | EP3334426A2 (es) |
| JP (1) | JP2018522936A (es) |
| KR (1) | KR20180037975A (es) |
| CN (1) | CN107921028A (es) |
| AU (1) | AU2016308704B2 (es) |
| BR (1) | BR112018000496A2 (es) |
| CA (1) | CA2991276A1 (es) |
| CL (1) | CL2018000391A1 (es) |
| HK (1) | HK1249408A1 (es) |
| IL (1) | IL256537A (es) |
| MX (1) | MX2018001903A (es) |
| PH (1) | PH12018500096A1 (es) |
| RU (1) | RU2018108804A (es) |
| WO (1) | WO2017029588A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018092020A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| WO2019053595A1 (en) | 2017-09-12 | 2019-03-21 | Novartis Ag | INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA |
| US20220401440A1 (en) * | 2019-11-18 | 2022-12-22 | Ideaya Biosciences, Inc. | Dosing regimens for a protein kinase c inhibitor |
| WO2024125543A1 (zh) * | 2022-12-16 | 2024-06-20 | 苏州科睿思制药有限公司 | 达洛色替的晶型及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2329263C2 (ru) | 2000-11-07 | 2008-07-20 | Новартис Аг | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| ITCO20110027A1 (it) * | 2011-07-21 | 2013-01-22 | Nuovo Pignone Spa | Turbomacchina centrifuga multistadio |
| US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| AU2014372166B2 (en) * | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| MX2016008363A (es) * | 2013-12-23 | 2016-09-08 | Novartis Ag | Combinaciones farmaceuticas. |
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| JP2018528949A (ja) * | 2015-08-28 | 2018-10-04 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法 |
-
2016
- 2016-08-11 JP JP2018507614A patent/JP2018522936A/ja active Pending
- 2016-08-11 AU AU2016308704A patent/AU2016308704B2/en not_active Expired - Fee Related
- 2016-08-11 BR BR112018000496A patent/BR112018000496A2/pt not_active IP Right Cessation
- 2016-08-11 CN CN201680047789.3A patent/CN107921028A/zh active Pending
- 2016-08-11 HK HK18108028.9A patent/HK1249408A1/zh unknown
- 2016-08-11 CA CA2991276A patent/CA2991276A1/en not_active Abandoned
- 2016-08-11 RU RU2018108804A patent/RU2018108804A/ru not_active Application Discontinuation
- 2016-08-11 WO PCT/IB2016/054841 patent/WO2017029588A2/en not_active Ceased
- 2016-08-11 US US15/751,954 patent/US20180243293A1/en not_active Abandoned
- 2016-08-11 KR KR1020187003995A patent/KR20180037975A/ko not_active Withdrawn
- 2016-08-11 EP EP16758285.7A patent/EP3334426A2/en not_active Withdrawn
- 2016-08-11 MX MX2018001903A patent/MX2018001903A/es unknown
-
2017
- 2017-12-25 IL IL256537A patent/IL256537A/en unknown
-
2018
- 2018-01-11 PH PH12018500096A patent/PH12018500096A1/en unknown
- 2018-02-13 CL CL2018000391A patent/CL2018000391A1/es unknown
-
2019
- 2019-08-08 US US16/535,214 patent/US20200246331A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016308704A1 (en) | 2018-02-08 |
| PH12018500096A1 (en) | 2018-07-23 |
| KR20180037975A (ko) | 2018-04-13 |
| RU2018108804A (ru) | 2019-09-16 |
| CA2991276A1 (en) | 2017-02-23 |
| HK1249408A1 (zh) | 2018-11-02 |
| IL256537A (en) | 2018-02-28 |
| US20180243293A1 (en) | 2018-08-30 |
| CL2018000391A1 (es) | 2018-07-13 |
| WO2017029588A2 (en) | 2017-02-23 |
| CN107921028A (zh) | 2018-04-17 |
| BR112018000496A2 (pt) | 2018-09-11 |
| JP2018522936A (ja) | 2018-08-16 |
| EP3334426A2 (en) | 2018-06-20 |
| US20200246331A1 (en) | 2020-08-06 |
| WO2017029588A3 (en) | 2017-04-20 |
| AU2016308704B2 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| PH12018500096A1 (en) | Mdm2 inhibitors for treating uveal melanoma | |
| CA2902116C (en) | Pyrrolopyridine derivatives and their use as inhibitors of ssao activity | |
| MX377032B (es) | Compuestos de dihidroquinolinsulfonamida de alquilo. | |
| MX362533B (es) | Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa. | |
| PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug | |
| PH12014501215A1 (en) | Peptide deformylase inhibitors | |
| MY187891A (en) | Tetrahydropyridine derivatives as fabi inhibitors | |
| NZ780408A (en) | Human plasma kallikrein inhibitors | |
| MX2019014773A (es) | Inhibidores de ccl2. | |
| EA202091668A2 (ru) | Ингибиторы калликреина плазмы человека | |
| SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز |